FAAH-mediated modulation of TLR3-induced neuroinflammation in the rat hippocampus

Journal of Neuroimmunology

Volumn 276, Issue 1-2, 2014, Pages 126-134

  Henry, Rebecca J ^a   Kerr, Daniel M ^a   Finn, David P ^a   Roche, Michelle ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Anandamide; Cannabinoid; Cytokine; Fatty acid amide hydrolase; Interferon; Virus

Indexed keywords

ALPHA INTERFERON; ANANDAMIDE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; N OLEOYLETHANOLAMINE; PALMIDROL; SUPPRESSOR OF CYTOKINE SIGNALING 1; TOLL LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR ALPHA; AMIDASE; BENZAMIDE DERIVATIVE; CARBAMIC ACID DERIVATIVE; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; CYTOKINE; ENZYME INHIBITOR; FATTY-ACID AMIDE HYDROLASE; INTERFERON INDUCING AGENT; MESSENGER RNA; POLYINOSINIC POLYCYTIDYLIC ACID; TLR3 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; ENZYME INHIBITION; HIPPOCAMPUS; IMMUNE RESPONSE; IMMUNOMODULATION; IN VIVO STUDY; MALE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; RAT; ANIMAL; CHEMICALLY INDUCED; DRUG ADMINISTRATION ROUTE; DRUG EFFECTS; ENCEPHALITIS; GENE EXPRESSION REGULATION; GENETICS; LIQUID CHROMATOGRAPHY; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; TANDEM MASS SPECTROMETRY; TOXICITY;

AMIDOHYDROLASES; ANIMALS; BENZAMIDES; CARBAMATES; CHROMATOGRAPHY, LIQUID; CYTOKINES; DRUG ADMINISTRATION ROUTES; ENCEPHALITIS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HIPPOCAMPUS; INTERFERON INDUCERS; MALE; POLY I-C; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TANDEM MASS SPECTROMETRY; TOLL-LIKE RECEPTOR 3;

EID: 84908501186     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.09.002     Document Type: Article

References (78)

1. Arroyo D.S., Soria J.A., Gaviglio E.A., Rodriguez-Galan M.C., Iribarren P. Toll-like receptors are key players in neurodegeneration. Int. Immunopharmacol. 2011, 11(10):1415-1421.
2. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Makriyannis A., et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001, 15(2):300-302.
3. Bisogno T., Di Marzo V. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol. Disord. Drug Targets 2010, 9(5):564-573.
4. Bowen J.L., Olson J.K. IFNgamma influences type I interferon response and susceptibility to Theiler's virus-induced demyelinating disease. Viral Immunol. 2013, 26(4):223-238.
5. Brudek T., Winge K., Agander T.K., Pakkenberg B. Screening of Toll-like receptors expression in multiple system atrophy brains. Neurochem. Res. 2013, 38(6):1252-1259.
6. Bsibsi M., Ravid R., Gveric D., van Noort J.M. Broad expression of Toll-like receptors in the human central nervous system. J. Neuropathol. Exp. Neurol. 2002, 61(11):1013-1021.
7. Burke N.N., Geoghegan E., Kerr D.M., Moriarty O., Finn D.P., Roche M. Altered neuropathic pain behaviour in a rat model of depression is associated with changes in inflammatory gene expression in the amygdala. Genes Brain Behav. 2013, 12(7):705-713.
8. Burke N.N., Llorente R., Marco E.M., Tong K., Finn D.P., Viveros M.P., et al. Maternal deprivation is associated with sex-dependent alterations in nociceptive behavior and neuroinflammatory mediators in the rat following peripheral nerve injury. J. Pain 2013, 14(10):1173-1184.
9. Correa F., Docagne F., Mestre L., Clemente D., Hernangomez M., Loria F., et al. A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem. Pharmacol. 2009, 77(1):86-100.
10. Correa F.G., Mestre L., Docagne F., Borrell J., Guaza C. The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis. Vitam. Horm. 2009, 81:207-230.
11. Correa F., Hernangomez M., Mestre L., Loria F., Spagnolo A., Docagne F., et al. Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB. Glia 2010, 58(2):135-147.
12. Correa F., Hernangomez-Herrero M., Mestre L., Loria F., Docagne F., Guaza C. The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain Behav. Immun. 2011, 25(4):736-749.
13. Costello D.A., Lynch M.A. Toll-like receptor 3 activation modulates hippocampal network excitability, via glial production of interferon-beta. Hippocampus 2013, 23(8):696-707.
14. Cunningham C., Campion S., Teeling J., Felton L., Perry V.H. The sickness behaviour and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded RNA (poly I:C). Brain Behav. Immun. 2007, 21(4):490-502.
15. De Fanti B.A., Martinez J.A. Central urocortin activation of sympathetic-regulated energy metabolism in Wistar rats. Brain Res. 2002, 930(1-2):37-41.
16. De Laurentiis A., Fernandez-Solari J., Mohn C., Burdet B., Zorrilla Zubilete M.A., Rettori V. The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor-alpha induced by lipopolysaccharide. J. Neuroimmunol. 2010, 221(1-2):32-41.
17. Degn M., Lambertsen K.L., Petersen G., Meldgaard M., Artmann A., Clausen B.H., et al. Changes in brain levels of N-acylethanolamines and 2-arachidonoylglycerol in focal cerebral ischemia in mice. J. Neurochem. 2007, 103(5):1907-1916.
18. Deleidi M., Isacson O. Viral and inflammatory triggers of neurodegenerative diseases. Sci. Transl. Med. 2012, 4(121):121ps123.
19. Downer E.J. Cannabinoids and innate immunity: taking a toll on neuroinflammation. ScientificWorldJournal 2011, 11:855-865.
20. Downer E.J., Clifford E., Gran B., Nel H.J., Fallon P.G., Moynagh P.N. Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis. J. Biol. Chem. 2011, 286(12):10316-10328.
21. Downer E.J., Clifford E., Amu S., Fallon P.G., Moynagh P.N. The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-beta expression via peroxisome proliferator-activated receptor-alpha. J. Biol. Chem. 2012, 287(30):25440-25453.
22. Duncan M., Galic M.A., Wang A., Chambers A.P., McCafferty D.M., McKay D.M., et al. Cannabinoid 1 receptors are critical for the innate immune response to TLR4 stimulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013, 305(3):R224-R231.
23. Esposito E., Cuzzocrea S. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. Mini Rev. Med. Chem. 2013, 13(2):237-255.
24. Facchinetti F., Del Giudice E., Furegato S., Passarotto M., Leon A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 2003, 41(2):161-168.
25. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 2005, 313(1):352-358.
26. Field R., Campion S., Warren C., Murray C., Cunningham C. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav. Immun. 2010, 24(6):996-1007.
27. Franklin A., Parmentier-Batteur S., Walter L., Greenberg D.A., Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J. Neurosci. 2003, 23(21):7767-7775.
28. Galic M.A., Riazi K., Henderson A.K., Tsutsui S., Pittman Q.J. Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats. Neurobiol. Dis. 2009, 36(2):343-351.
29. Geiger K.D., Nash T.C., Sawyer S., Krahl T., Patstone G., Reed J.C., et al. Interferon-gamma protects against herpes simplex virus type 1-mediated neuronal death. Virology 1997, 238(2):189-197.
30. Gibney S.M., McGuinness B., Prendergast C., Harkin A., Connor T.J. Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav. Immun. 2013, 28:170-181.
31. Gurley C., Nichols J., Liu S., Phulwani N.K., Esen N., Kielian T. Microglia and astrocyte activation by Toll-like receptor ligands: modulation by PPAR-gamma agonists. PPAR Res. 2008, 2008:453120.
32. Hernangomez M., Mestre L., Correa F.G., Loria F., Mecha M., Inigo P.M., et al. CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. Glia 2012, 60(9):1437-1450.
33. Holmes C., Cunningham C., Zotova E., Woolford J., Dean C., Kerr S., et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009, 73(10):768-774.
34. Jean-Gilles L., Gran B., Constantinescu C.S. Interaction between cytokines, cannabinoids and the nervous system. Immunobiology 2010, 215(8):606-610.
35. Katafuchi T., Kondo T., Yasaka T., Kubo K., Take S., Yoshimura M. Prolonged effects of polyriboinosinic:polyribocytidylic acid on spontaneous running wheel activity and brain interferon-alpha mRNA in rats: a model for immunologically induced fatigue. Neuroscience 2003, 120(3):837-845.
36. Katafuchi T., Kondo T., Take S., Yoshimura M. Enhanced expression of brain interferon-alpha and serotonin transporter in immunologically induced fatigue in rats. Eur. J. Neurosci. 2005, 22(11):2817-2826.
37. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 2003, 9(1):76-81.
38. Kerr D.M., Burke N.N., Ford G.K., Connor T.J., Harhen B., Egan L.J., et al. Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor. Neuroscience 2012, 204:53-63.
39. Kerr D.M., Downey L., Conboy M., Finn D.P., Roche M. Alterations in the endocannabinoid system in the rat valproic acid model of autism. Behav. Brain Res. 2013, 249:124-132.
40. Kerr D.M., Harhen B., Okine B.N., Egan L.J., Finn D.P., Roche M. The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. Br. J. Pharmacol. 2013, 169(4):808-819.
41. Kranjac D., McLinden K.A., Koster K.M., Kaldenbach D.L., Chumley M.J., Boehm G.W. Peripheral administration of poly I:C disrupts contextual fear memory consolidation and BDNF expression in mice. Behav. Brain Res. 2012, 228(2):452-457.
42. Lee J., Kim S.J., Son T.G., Chan S.L., Mattson M.P. Interferon-gamma is up-regulated in the hippocampus in response to intermittent fasting and protects hippocampal neurons against excitotoxicity. J. Neurosci. Res. 2006, 83(8):1552-1557.
43. Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 2010, 58(3):253-263.
44. Lin W., Bailey S.L., Ho H., Harding H.P., Ron D., Miller S.D., et al. The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage. J. Clin. Invest. 2007, 117(2):448-456.
45. Loria F., Petrosino S., Mestre L., Spagnolo A., Correa F., Hernangomez M., et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur. J. Neurosci. 2008, 28(4):633-641.
46. Loria F., Petrosino S., Hernangomez M., Mestre L., Spagnolo A., Correa F., et al. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol. Dis. 2010, 37(1):166-176.
47. Mestre L., Correa F., Arevalo-Martin A., Molina-Holgado E., Valenti M., Ortar G., et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem. 2005, 92(6):1327-1339.
48. Molina-Holgado F., Lledo A., Guaza C. Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 1997, 8(8):1929-1933.
49. Molina-Holgado F., Molina-Holgado E., Guaza C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett. 1998, 433(1-2):139-142.
50. Muhl H., Pfeilschifter J. Anti-inflammatory properties of pro-inflammatory interferon-gamma. Int. Immunopharmacol. 2003, 3(9):1247-1255.
51. Murphy N., Cowley T.R., Blau C.W., Dempsey C.N., Noonan J., Gowran A., et al. The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation. J. Neuroinflammation 2012, 9:79.
52. Nagarkatti P., Pandey R., Rieder S.A., Hegde V.L., Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med. Chem. 2009, 1(7):1333-1349.
53. Naves R., Singh S.P., Cashman K.S., Rowse A.L., Axtell R.C., Steinman L., et al. The interdependent, overlapping, and differential roles of type I and II IFNs in the pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 2013, 191(6):2967-2977.
54. Okun E., Griffioen K., Barak B., Roberts N.J., Castro K., Pita M.A., et al. Toll-like receptor 3 inhibits memory retention and constrains adult hippocampal neurogenesis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(35):15625-15630.
55. Ortega-Gutierrez S., Molina-Holgado E., Guaza C. Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia 2005, 52(2):163-168.
56. Owens T. Toll-like receptors in neurodegeneration. Curr. Top. Microbiol. Immunol. 2009, 336:105-120.
57. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2006, 6th ed.
58. Perry V.H. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav. Immun. 2004, 18(5):407-413.
59. Piomelli D., Tarzia G., Duranti A., Tontini A., Mor M., Compton T.R., et al. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 2006, 12(1):21-38.
60. Prinz M., Schmidt H., Mildner A., Knobeloch K.P., Hanisch U.K., Raasch J., et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008, 28(5):675-686.
61. Puffenbarger R.A., Boothe A.C., Cabral G.A. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 2000, 29(1):58-69.
62. Roche M., Kelly J.P., O'Driscoll M., Finn D.P. Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats. Immunology 2008, 125(2):263-271.
63. Rodriguez M., Zoecklein L.J., Howe C.L., Pavelko K.D., Gamez J.D., Nakane S., et al. Gamma interferon is critical for neuronal viral clearance and protection in a susceptible mouse strain following early intracranial Theiler's murine encephalomyelitis virus infection. J. Virol. 2003, 77(22):12252-12265.
64. Ryu H.J., Kim J.E., Kim M.J., Kwon H.J., Suh S.W., Song H.K., et al. The protective effects of interleukin-18 and interferon-gamma on neuronal damages in the rat hippocampus following status epilepticus. Neuroscience 2010, 170(3):711-721.
65. Salaria S., Badkoobehi H., Rockenstein E., Crews L., Chana G., Masliah E., et al. Toll-like receptor pathway gene expression is associated with human immunodeficiency virus-associated neurodegeneration. J. Neurovirol. 2007, 13(6):496-503.
66. Sancho R., Calzado M.A., Di Marzo V., Appendino G., Munoz E. Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. Mol. Pharmacol. 2003, 63(2):429-438.
67. Scuderi C., Steardo L. Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease. CNS Neurol. Disord. Drug Targets 2013, 12(1):62-69.
68. So E.Y., Kang M.H., Kim B.S. Induction of chemokine and cytokine genes in astrocytes following infection with Theiler's murine encephalomyelitis virus is mediated by the Toll-like receptor 3. Glia 2006, 53(8):858-867.
69. Solorzano C., Antonietti F., Duranti A., Tontini A., Rivara S., Lodola A., et al. Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors. J. Med. Chem. 2010, 53(15):5770-5781.
70. Steiner A.A., Molchanova A.Y., Dogan M.D., Patel S., Petervari E., Balasko M., et al. The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors. J. Physiol. 2011, 589(Pt 9):2415-2431.
71. Teeling J.L., Perry V.H. Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms. Neuroscience 2009, 158(3):1062-1073.
72. Teige I., Liu Y., Issazadeh-Navikas S. IFN-beta inhibits T cell activation capacity of central nervous system APCs. J. Immunol. 2006, 177(6):3542-3553.
73. Tham C.S., Whitaker J., Luo L., Webb M. Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators. FEBS Lett. 2007, 581(16):2899-2904.
74. Tsuboi K., Takezaki N., Ueda N. The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem. Biodivers. 2007, 4(8):1914-1925.
75. van Noort J.M., Bsibsi M. Toll-like receptors in the CNS: implications for neurodegeneration and repair. Prog. Brain Res. 2009, 175:139-148.
76. Wang Q., Peng Y., Chen S., Gou X., Hu B., Du J., et al. Pretreatment with electroacupuncture induces rapid tolerance to focal cerebral ischemia through regulation of endocannabinoid system. Stroke 2009, 40(6):2157-2164.
77. Zhao W., Wang L., Zhang M., Wang P., Zhang L., Yuan C., et al. Peroxisome proliferator-activated receptor gamma negatively regulates IFN-beta production in Toll-like receptor (TLR) 3- and TLR4-stimulated macrophages by preventing interferon regulatory factor 3 binding to the IFN-beta promoter. J. Biol. Chem. 2011, 286(7):5519-5528.
78. Zhou H., Zhang Z., Wei H., Wang F., Guo F., Gao Z., et al. Activation of STAT3 is involved in neuroprotection by electroacupuncture pretreatment via cannabinoid CB1 receptors in rats. Brain Res. 2013, 1529:154-164.